ER/PR(+), Her2(-) Breast Cancer
Oncology
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target ER/PR(+), Her2(-) Breast Cancer?
There are 1 clinical trial targeting ER/PR(+), Her2(-) Breast Cancer tracked by BioSniper.
What is the prevalence of ER/PR(+), Her2(-) Breast Cancer?
The estimated prevalence of ER/PR(+), Her2(-) Breast Cancer is approximately 287.0 per 100,000 population.
Deep-dive into ER/PR(+), Her2(-) Breast Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis